Optimize your therapeutic candidate selection when you partner with the JAX Preclinical Services team. Experience a seamless workflow to accelerate your success and advance immunological, autoimmune, and inflammatory disease research faster. No matter what class of therapeutic you're exploring, partner with us for custom solutions that get your project from initial investigations to IND filing.
Antibody-based therapeutics offer incredible versatility for treating disease. JAX Preclinical Service team has decades of expertise in executing in vivo PK and pharmacodynamic (PD) studies using established assays to quantify test article plasma concentrations to derive PK/PD data.
Our humanized PK platform (HuPK™) delivers predictive data such as half-life, clearance values, area under the curve (AUC), and volume of distribution (Vd) to help you derive the optimal first-in-human (FIH) dose for candidate therapeutics. These well-established, thoroughly characterized human FcRn mice are ideal for generating translationally relevant PK data therapeutic antibody candidates, reducing the risk of clinical trial failures and accelerating your path to regulatory approval.
The JAX CRS Evaluation Study gives drug developers the first opportunity to test immunomodulatory therapeutics through an in vivo assay that examines efficacy, cytokine response, and downstream organ effects in a diverse patient population. Traditional in vitro assays are simply unable to provide the necessary details on systemic immune response and downstream organ impacts, which is crucial for determining the true efficacy and safety of the therapeutic.
Fast-Track clinical trials for immunotherapeutics and antibody therapeutics evaluations in Hu-NSG with JAX Cytokine Assay Services.
Our preclinical testing team offers efficacy studies to evaluate therapeutic compounds to treat a variety of autoimmune disorders using the most robust published mouse models. Improve your candidate selection and make go / no-go decisions for your project with support from JAX scientists who understand the underlying biology of the model systems. Partner with us for optimized execution of studies based on the test article's mode of action (MOA). Get translationally relevant data that supports the expected MOA without wasting your resources or time with inconclusive results and repeat experiments.
Humanized CD34+ mice are used to study immuno-oncology, infectious diseases and graft rejection research. This model has the longest research span, over 12 months with a functional human immune system and displays T-cell dependent inflammatory responses, with no donor cell immune reactivity towards host. Humanized PBMC mice are used to study and evaluate compounds for infectious diseases and graft rejection research. These models have the fastest engraftment rate using adult peripheral blood mononuclear cells, which enables short-term studies requiring a strong effector and memory T cell function.
Dr. Lenka Sadilkova, Director Non-clinical Projects at Mablink Bioscience - Eli Lilly, presented her work as part of the virtual summit, "Modeling Human Immunobiology In Vivo: Replacing NHPs with Humanized Mice in Preclinical Antibody Testing", that took place on September 23, 2025.
Not what you're looking for?
Visit our Resource Hub
